Page last updated: 2024-11-12

demethylcantharidin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

demethylcantharidin: has antineoplastic activity; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID12251907
CHEMBL ID1237212
MeSH IDM0437627

Synonyms (6)

Synonym
nsc-59023
nsc-14003
CHEMBL1237212
demethylcantharidin
isocantharidin
bdbm50366474
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Protein phosphatase 1BHomo sapiens (human)IC50 (µMol)3.64500.00031.51235.3100AID164498; AID164499
Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B Gallus gallus (chicken)IC50 (µMol)2.50000.00010.41982.9000AID164509; AID200731
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (8)

Processvia Protein(s)Taxonomy
protein dephosphorylationProtein phosphatase 1BHomo sapiens (human)
N-terminal protein myristoylationProtein phosphatase 1BHomo sapiens (human)
negative regulation of interferon-beta productionProtein phosphatase 1BHomo sapiens (human)
peptidyl-threonine dephosphorylationProtein phosphatase 1BHomo sapiens (human)
negative regulation of canonical NF-kappaB signal transductionProtein phosphatase 1BHomo sapiens (human)
negative regulation of defense response to virusProtein phosphatase 1BHomo sapiens (human)
negative regulation of non-canonical NF-kappaB signal transductionProtein phosphatase 1BHomo sapiens (human)
positive regulation of canonical Wnt signaling pathwayProtein phosphatase 1BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
magnesium ion bindingProtein phosphatase 1BHomo sapiens (human)
protein serine/threonine phosphatase activityProtein phosphatase 1BHomo sapiens (human)
protein bindingProtein phosphatase 1BHomo sapiens (human)
myosin phosphatase activityProtein phosphatase 1BHomo sapiens (human)
manganese ion bindingProtein phosphatase 1BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
nucleolusProtein phosphatase 1BHomo sapiens (human)
cytosolProtein phosphatase 1BHomo sapiens (human)
membraneProtein phosphatase 1BHomo sapiens (human)
nucleusProtein phosphatase 1BHomo sapiens (human)
cytosolProtein phosphatase 1BHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (131)

Assay IDTitleYearJournalArticle
AID478768Cytotoxicity against human A2780 cells after 72 hrs by MTT assay2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
Synthesis and biological activity of Delta-5,6-norcantharimides: importance of the 5,6-bridge.
AID1306332Cytotoxicity against human A549 cells after 36 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs.
AID1306326Cell cycle arrest in human MCF7 cells assessed as accumulation at S phase at 4 uM after 24 hrs by propidium iodide staining-based flow cytometry (Rvb = 15.95 to 25.74%)2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs.
AID300548Cytotoxicity against human H460 cells after 72 hrs by MTT assay2007Bioorganic & medicinal chemistry, Sep-15, Volume: 15, Issue:18
Norcantharimides, synthesis and anticancer activity: Synthesis of new norcantharidin analogues and their anticancer evaluation.
AID300544Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay2007Bioorganic & medicinal chemistry, Sep-15, Volume: 15, Issue:18
Norcantharimides, synthesis and anticancer activity: Synthesis of new norcantharidin analogues and their anticancer evaluation.
AID1306331Cytotoxicity against human MCF7 cells after 36 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs.
AID119501Toxicity in male nude mice measured as N (no. of deaths), at 4 mg/kg (ip) given on days 1, 5 and 92001Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13
Potential new antitumor agents from an innovative combination of demethylcantharidin, a modified traditional Chinese medicine, with a platinum moiety.
AID1275331Cytotoxicity in zebrafish embryo assessed as survival rate at 50 ppm after 80 mins relative to control2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
Amphiphilic nanoparticles of resveratrol-norcantharidin to enhance the toxicity in zebrafish embryo.
AID300550Cytotoxicity against human A431 cells after 72 hrs by MTT assay2007Bioorganic & medicinal chemistry, Sep-15, Volume: 15, Issue:18
Norcantharimides, synthesis and anticancer activity: Synthesis of new norcantharidin analogues and their anticancer evaluation.
AID164495Inhibitory activity against protein phosphatase-1 from rabbit skeletal muscle2004Bioorganic & medicinal chemistry letters, Apr-19, Volume: 14, Issue:8
Modified norcantharidins; synthesis, protein phosphatases 1 and 2A inhibition, and anticancer activity.
AID300556Cytotoxicity against human SJG2 cells after 72 hrs by MTT assay2007Bioorganic & medicinal chemistry, Sep-15, Volume: 15, Issue:18
Norcantharimides, synthesis and anticancer activity: Synthesis of new norcantharidin analogues and their anticancer evaluation.
AID164499Inhibitory concentration against protein phosphatase 1 (PP1) was determined2001Bioorganic & medicinal chemistry letters, Nov-19, Volume: 11, Issue:22
Cantharimides: a new class of modified cantharidin analogues inhibiting protein phosphatases 1 and 2A.
AID300552Cytotoxicity against human DU145 cells after 72 hrs by MTT assay2007Bioorganic & medicinal chemistry, Sep-15, Volume: 15, Issue:18
Norcantharimides, synthesis and anticancer activity: Synthesis of new norcantharidin analogues and their anticancer evaluation.
AID301933Selectivity ratio of IC50 for rabbit skeletal muscle PP1 over IC50 for human PP2A2007Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23
Synthesis and biological evaluation of norcantharidin analogues: towards PP1 selectivity.
AID120880Ratio of the relative tumor volume in the Tx group over the control group at day 60, at 2 mg/kg dose (ip) given on days 1, 5 and 9 (In vivo antitumor activity in nude mice)2001Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13
Potential new antitumor agents from an innovative combination of demethylcantharidin, a modified traditional Chinese medicine, with a platinum moiety.
AID1306339Induction of apoptosis in human MCF7 cells assessed as necrotic cells at 8 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 0.021 to 3.8%)2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs.
AID296228Cytotoxicity against human DU145 cells2007Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12
Heterocyclic substituted cantharidin and norcantharidin analogues--synthesis, protein phosphatase (1 and 2A) inhibition, and anti-cancer activity.
AID200560Inhibition against PP1 at 100 uM2002Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3
The first two cantharidin analogues displaying PP1 selectivity.
AID617847Antiproliferative activity against human DU145 cells after 72 hrs by MTT assay2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
Norcantharimide analogues possessing terminal phosphate esters and their anti-cancer activity.
AID164513Inhibitory activity against protein phosphatase 2A from human red blood cells2004Bioorganic & medicinal chemistry letters, Apr-19, Volume: 14, Issue:8
Modified norcantharidins; synthesis, protein phosphatases 1 and 2A inhibition, and anticancer activity.
AID9818850% growth inhibition of L1210 (murine leukemia) cell line compared with untreated control cells2004Bioorganic & medicinal chemistry letters, Apr-19, Volume: 14, Issue:8
Modified norcantharidins; synthesis, protein phosphatases 1 and 2A inhibition, and anticancer activity.
AID1306330Cell cycle arrest in human MCF7 cells assessed as accumulation at G2/M phase at 8 uM after 24 hrs by propidium iodide staining-based flow cytometry (Rvb = 3.73 to 10.75%)2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs.
AID478765Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
Synthesis and biological activity of Delta-5,6-norcantharimides: importance of the 5,6-bridge.
AID10182Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Anhydride modified cantharidin analogues: synthesis, inhibition of protein phosphatases 1 and 2A and anticancer activity.
AID233872Selectivity expressed as the ratio of PP2A/PP1 was determined2001Bioorganic & medicinal chemistry letters, Nov-19, Volume: 11, Issue:22
Cantharimides: a new class of modified cantharidin analogues inhibiting protein phosphatases 1 and 2A.
AID1306325Cell cycle arrest in human MCF7 cells assessed as accumulation at S phase at 2 uM after 24 hrs by propidium iodide staining-based flow cytometry (Rvb = 15.95 to 25.74%)2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs.
AID119504Toxicity in male nude mice measured as N (no. of deaths), at 8 mg/kg (ip) given on days 1, 5 and 92001Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13
Potential new antitumor agents from an innovative combination of demethylcantharidin, a modified traditional Chinese medicine, with a platinum moiety.
AID1306329Cell cycle arrest in human MCF7 cells assessed as accumulation at G2/M phase at 4 uM after 24 hrs by propidium iodide staining-based flow cytometry (Rvb = 3.73 to 10.75%)2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs.
AID301934Selectivity ratio of IC50 for rabbit skeletal muscle PP1 over IC50 for bovine brain PP2B2007Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23
Synthesis and biological evaluation of norcantharidin analogues: towards PP1 selectivity.
AID200731Concentration required to inhibit the action of protein phosphatase 2A2002Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3
The first two cantharidin analogues displaying PP1 selectivity.
AID617844Antiproliferative activity against human A2780 cells after 72 hrs by MTT assay2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
Norcantharimide analogues possessing terminal phosphate esters and their anti-cancer activity.
AID10058Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Anhydride modified cantharidin analogues: synthesis, inhibition of protein phosphatases 1 and 2A and anticancer activity.
AID478771Cytotoxicity against human DU145 cells after 72 hrs by MTT assay2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
Synthesis and biological activity of Delta-5,6-norcantharimides: importance of the 5,6-bridge.
AID526427Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 assessed as inhibition of parasite LDH activity at 100 uM after 72 hrs by malstat reagent method2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
The antiplasmodial activity of norcantharidin analogs.
AID120881Ratio of the relative tumor volume in the Tx group over the control group at day 60, at 4 mg/kg dose (ip) given on days 1, 5 and 9 (In vivo antitumor activity in nude mice)2001Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13
Potential new antitumor agents from an innovative combination of demethylcantharidin, a modified traditional Chinese medicine, with a platinum moiety.
AID478775Inhibition of rabbit skeletal muscle protein phosphatase 1 assessed as free phosphate ion release after 60 mins by malachite green method2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
Synthesis and biological activity of Delta-5,6-norcantharimides: importance of the 5,6-bridge.
AID1306342Induction of apoptosis in human MCF7 cells assessed as late apoptotic cells at 4 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 5.92 to 9.33%)2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs.
AID164509Inhibitory concentration against protein phosphatase 2A (PP2A) was determined2001Bioorganic & medicinal chemistry letters, Nov-19, Volume: 11, Issue:22
Cantharimides: a new class of modified cantharidin analogues inhibiting protein phosphatases 1 and 2A.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1306334Cytotoxicity against HEK293T cells after 36 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs.
AID1175303Cytotoxicity against human HCT8 cells after 48 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Jan-15, Volume: 25, Issue:2
Synthesis and biological evaluation of norcantharidin derivatives as protein phosphatase-1 inhibitors.
AID1306347Induction of apoptosis in human MCF7 cells assessed as early apoptotic cells at 8 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 2.45 to 6.92%)2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs.
AID512131Cytotoxicity against rat hepatocyte cells after 48 hrs by MTT assay2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Therapeutic effects of cantharidin analogues without bridging ether oxygen on human hepatocellular carcinoma cells.
AID200733Inhibition against PP2A at 100 uM2002Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3
The first two cantharidin analogues displaying PP1 selectivity.
AID524792Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1275330Cytotoxicity in zebrafish embryo assessed as survival rate at 25 ppm after 80 mins relative to control2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
Amphiphilic nanoparticles of resveratrol-norcantharidin to enhance the toxicity in zebrafish embryo.
AID478766Cytotoxicity against human SW480 cells after 72 hrs by MTT assay2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
Synthesis and biological activity of Delta-5,6-norcantharimides: importance of the 5,6-bridge.
AID1306350Induction of apoptosis in human MCF7 cells assessed as viable cells at 4 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 80 to 91.6%)2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs.
AID1306349Induction of apoptosis in human MCF7 cells assessed as viable cells at 2 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 80 to 91.6%)2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID8430050% growth inhibition of HT-29 (human colorectal carcinoma) cell line compared with untreated control cells2004Bioorganic & medicinal chemistry letters, Apr-19, Volume: 14, Issue:8
Modified norcantharidins; synthesis, protein phosphatases 1 and 2A inhibition, and anticancer activity.
AID1306324Cell cycle arrest in human MCF7 cells assessed as accumulation at G0/G1 phase at 8 uM after 24 hrs by propidium iodide staining-based flow cytometry (Rvb = 64.68 to 80.32%)2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs.
AID1306336Induction of apoptosis in human MCF7 cells assessed as necrotic cells at 1 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 0.021 to 3.8%)2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs.
AID296226Cytotoxicity against human H460 cells2007Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12
Heterocyclic substituted cantharidin and norcantharidin analogues--synthesis, protein phosphatase (1 and 2A) inhibition, and anti-cancer activity.
AID7840150% growth inhibition of H460 (human lung carcinoma) cell line compared with untreated control cells2004Bioorganic & medicinal chemistry letters, Apr-19, Volume: 14, Issue:8
Modified norcantharidins; synthesis, protein phosphatases 1 and 2A inhibition, and anticancer activity.
AID1306341Induction of apoptosis in human MCF7 cells assessed as late apoptotic cells at 2 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 5.92 to 9.33%)2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs.
AID1306323Cell cycle arrest in human MCF7 cells assessed as accumulation at G0/G1 phase at 4 uM after 24 hrs by propidium iodide staining-based flow cytometry (Rvb = 64.68 to 80.32%)2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs.
AID301931Inhibition of PP2A in human red blood cells2007Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23
Synthesis and biological evaluation of norcantharidin analogues: towards PP1 selectivity.
AID7243450% growth inhibition of G401 (human kidney carcinoma) cell line compared with untreated control cells2004Bioorganic & medicinal chemistry letters, Apr-19, Volume: 14, Issue:8
Modified norcantharidins; synthesis, protein phosphatases 1 and 2A inhibition, and anticancer activity.
AID478769Cytotoxicity against human H460 cells after 72 hrs by MTT assay2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
Synthesis and biological activity of Delta-5,6-norcantharimides: importance of the 5,6-bridge.
AID998450% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells2004Bioorganic & medicinal chemistry letters, Apr-19, Volume: 14, Issue:8
Modified norcantharidins; synthesis, protein phosphatases 1 and 2A inhibition, and anticancer activity.
AID296227Cytotoxicity against human A431 cells2007Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12
Heterocyclic substituted cantharidin and norcantharidin analogues--synthesis, protein phosphatase (1 and 2A) inhibition, and anti-cancer activity.
AID226994Selectivity was evaluated against protein phosphatase 12002Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3
The first two cantharidin analogues displaying PP1 selectivity.
AID1306328Cell cycle arrest in human MCF7 cells assessed as accumulation at G2/M phase at 2 uM after 24 hrs by propidium iodide staining-based flow cytometry (Rvb = 3.73 to 10.75%)2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs.
AID1306340Induction of apoptosis in human MCF7 cells assessed as late apoptotic cells at 1 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 5.92 to 9.33%)2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs.
AID478772Cytotoxicity against human BE(2)-C cells after 72 hrs by MTT assay2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
Synthesis and biological activity of Delta-5,6-norcantharimides: importance of the 5,6-bridge.
AID296230Cytotoxicity against human SJ-G2 cells2007Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12
Heterocyclic substituted cantharidin and norcantharidin analogues--synthesis, protein phosphatase (1 and 2A) inhibition, and anti-cancer activity.
AID164508Inhibitory activity against partially purified (chicken skeletal muscle) Protein phosphatase 2A2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Anhydride modified cantharidin analogues: synthesis, inhibition of protein phosphatases 1 and 2A and anticancer activity.
AID296220Inhibition of Protein phosphatase 12007Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12
Heterocyclic substituted cantharidin and norcantharidin analogues--synthesis, protein phosphatase (1 and 2A) inhibition, and anti-cancer activity.
AID478773Cytotoxicity against human SJ-G2 cells after 72 hrs by MTT assay2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
Synthesis and biological activity of Delta-5,6-norcantharimides: importance of the 5,6-bridge.
AID1306345Induction of apoptosis in human MCF7 cells assessed as early apoptotic cells at 2 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 2.45 to 6.92%)2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs.
AID1306351Induction of apoptosis in human MCF7 cells assessed as viable cells at 8 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 80 to 91.6%)2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs.
AID617841Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
Norcantharimide analogues possessing terminal phosphate esters and their anti-cancer activity.
AID81703Inhibitory activity against colon tumor cell line HCT116 after 72 hr continuous exposure to compound2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Anhydride modified cantharidin analogues: synthesis, inhibition of protein phosphatases 1 and 2A and anticancer activity.
AID124927In vivo antitumor activity in SK-Hep-1 sc-Inoculated Xenograft in male nude mice dosed at 2 mg/kg (ip)on days 1,5 and 9; Not active2001Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13
Potential new antitumor agents from an innovative combination of demethylcantharidin, a modified traditional Chinese medicine, with a platinum moiety.
AID478776Inhibition of human red blood cells protein phosphatase 2A assessed as free phosphate ion release after 60 mins by malachite green method2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
Synthesis and biological activity of Delta-5,6-norcantharimides: importance of the 5,6-bridge.
AID119500Toxicity in male nude mice measured as N (no. of deaths), at 2 mg/kg (ip) given on days 1, 5 and 92001Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13
Potential new antitumor agents from an innovative combination of demethylcantharidin, a modified traditional Chinese medicine, with a platinum moiety.
AID300546Cytotoxicity against human A2780 cells after 72 hrs by MTT assay2007Bioorganic & medicinal chemistry, Sep-15, Volume: 15, Issue:18
Norcantharimides, synthesis and anticancer activity: Synthesis of new norcantharidin analogues and their anticancer evaluation.
AID84450Inhibitory activity against colon tumor cell line HT-29 after 72 hr continuous exposure to compound2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Anhydride modified cantharidin analogues: synthesis, inhibition of protein phosphatases 1 and 2A and anticancer activity.
AID296222Cytotoxicity against human HT29 cells2007Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12
Heterocyclic substituted cantharidin and norcantharidin analogues--synthesis, protein phosphatase (1 and 2A) inhibition, and anti-cancer activity.
AID617845Antiproliferative activity against human H460 cells after 72 hrs by MTT assay2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
Norcantharimide analogues possessing terminal phosphate esters and their anti-cancer activity.
AID617848Antiproliferative activity against human BE(2)-C cells after 72 hrs by MTT assay2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
Norcantharimide analogues possessing terminal phosphate esters and their anti-cancer activity.
AID296221Inhibition of Protein phosphatase 2A2007Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12
Heterocyclic substituted cantharidin and norcantharidin analogues--synthesis, protein phosphatase (1 and 2A) inhibition, and anti-cancer activity.
AID526434Inhibition of human PP1 expressed in Escherichia coli BL212010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
The antiplasmodial activity of norcantharidin analogs.
AID300542Cytotoxicity against human SW480 cells after 72 hrs by MTT assay2007Bioorganic & medicinal chemistry, Sep-15, Volume: 15, Issue:18
Norcantharimides, synthesis and anticancer activity: Synthesis of new norcantharidin analogues and their anticancer evaluation.
AID235534The compound was tested for the selectivity against protein phosphatases 2A2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Anhydride modified cantharidin analogues: synthesis, inhibition of protein phosphatases 1 and 2A and anticancer activity.
AID120884Ratio of the relative tumor volume in the Tx group over the control group at day 60, at 8 mg/kg dose (ip) given on days 1, 5 and 9 (In vivo antitumor activity in nude mice)2001Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13
Potential new antitumor agents from an innovative combination of demethylcantharidin, a modified traditional Chinese medicine, with a platinum moiety.
AID1275332Antibacterial activity against Escherichia coli assessed as inhibition of microbial growth2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
Amphiphilic nanoparticles of resveratrol-norcantharidin to enhance the toxicity in zebrafish embryo.
AID1175302Cytotoxicity against human HeLa cells after 48 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Jan-15, Volume: 25, Issue:2
Synthesis and biological evaluation of norcantharidin derivatives as protein phosphatase-1 inhibitors.
AID200558Inhibitory concentration against PP1 was determined2002Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3
The first two cantharidin analogues displaying PP1 selectivity.
AID1306327Cell cycle arrest in human MCF7 cells assessed as accumulation at S phase at 8 uM after 24 hrs by propidium iodide staining-based flow cytometry (Rvb = 15.95 to 25.74%)2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs.
AID1175300Cytotoxicity against human A549 cells after 48 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Jan-15, Volume: 25, Issue:2
Synthesis and biological evaluation of norcantharidin derivatives as protein phosphatase-1 inhibitors.
AID617846Antiproliferative activity against human A431 cells after 72 hrs by MTT assay2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
Norcantharimide analogues possessing terminal phosphate esters and their anti-cancer activity.
AID1306348Induction of apoptosis in human MCF7 cells assessed as viable cells at 1 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 80 to 91.6%)2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs.
AID124934In vivo antitumor activity in SK-Hep-1 sc-Inoculated Xenograft in male nude mice dosed at 8 mg/kg (ip)on days 1,5 and 92001Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13
Potential new antitumor agents from an innovative combination of demethylcantharidin, a modified traditional Chinese medicine, with a platinum moiety.
AID617842Antiproliferative activity against human SW480 cells after 72 hrs by MTT assay2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
Norcantharimide analogues possessing terminal phosphate esters and their anti-cancer activity.
AID1306346Induction of apoptosis in human MCF7 cells assessed as early apoptotic cells at 4 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 2.45 to 6.92%)2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs.
AID300540Cytotoxicity against human HT29 cells after 72 hrs by MTT assay2007Bioorganic & medicinal chemistry, Sep-15, Volume: 15, Issue:18
Norcantharimides, synthesis and anticancer activity: Synthesis of new norcantharidin analogues and their anticancer evaluation.
AID2908Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound2000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Anhydride modified cantharidin analogues: synthesis, inhibition of protein phosphatases 1 and 2A and anticancer activity.
AID1175304Cytotoxicity against human WI38 cells after 48 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Jan-15, Volume: 25, Issue:2
Synthesis and biological evaluation of norcantharidin derivatives as protein phosphatase-1 inhibitors.
AID1306333Cytotoxicity against human HeLa cells after 36 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs.
AID296225Cytotoxicity against human A2780 cells2007Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12
Heterocyclic substituted cantharidin and norcantharidin analogues--synthesis, protein phosphatase (1 and 2A) inhibition, and anti-cancer activity.
AID1306322Cell cycle arrest in human MCF7 cells assessed as accumulation at G0/G1 phase at 2 uM after 24 hrs by propidium iodide staining-based flow cytometry (Rvb = 64.68 to 80.32%)2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs.
AID512130Cytotoxicity against human SKHEP1 cells after 48 hrs by MTT assay2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Therapeutic effects of cantharidin analogues without bridging ether oxygen on human hepatocellular carcinoma cells.
AID1306344Induction of apoptosis in human MCF7 cells assessed as early apoptotic cells at 1 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 2.45 to 6.92%)2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs.
AID617849Antiproliferative activity against human SJ-G2 cells after 72 hrs by MTT assay2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
Norcantharimide analogues possessing terminal phosphate esters and their anti-cancer activity.
AID1175305Partition coefficient, log P of the compound2015Bioorganic & medicinal chemistry letters, Jan-15, Volume: 25, Issue:2
Synthesis and biological evaluation of norcantharidin derivatives as protein phosphatase-1 inhibitors.
AID119494Toxicity in male nude mice measured as N (no. of deaths), at 10 mg/kg (ip) given on days 1, 5 and 92001Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13
Potential new antitumor agents from an innovative combination of demethylcantharidin, a modified traditional Chinese medicine, with a platinum moiety.
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID296223Cytotoxicity against human SW480 cells2007Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12
Heterocyclic substituted cantharidin and norcantharidin analogues--synthesis, protein phosphatase (1 and 2A) inhibition, and anti-cancer activity.
AID164498Inhibitory activity against recombinant Protein phosphatase 12000Bioorganic & medicinal chemistry letters, Aug-07, Volume: 10, Issue:15
Anhydride modified cantharidin analogues: synthesis, inhibition of protein phosphatases 1 and 2A and anticancer activity.
AID1306343Induction of apoptosis in human MCF7 cells assessed as late apoptotic cells at 8 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 5.92 to 9.33%)2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs.
AID124919In vivo antitumor activity in SK-Hep-1 sc-Inoculated Xenograft in male nude mice dosed at 10 mg/kg (ip)on days 1,5 and 9; Acutely toxic2001Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13
Potential new antitumor agents from an innovative combination of demethylcantharidin, a modified traditional Chinese medicine, with a platinum moiety.
AID512129Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay2010European journal of medicinal chemistry, Sep, Volume: 45, Issue:9
Therapeutic effects of cantharidin analogues without bridging ether oxygen on human hepatocellular carcinoma cells.
AID526435Inhibition of human PP2A expressed in Escherichia coli BL212010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
The antiplasmodial activity of norcantharidin analogs.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1306337Induction of apoptosis in human MCF7 cells assessed as necrotic cells at 2 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 0.021 to 3.8%)2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs.
AID1275329Cytotoxicity in zebrafish embryo assessed as survival rate at 10 ppm after 80 mins relative to control2016Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3
Amphiphilic nanoparticles of resveratrol-norcantharidin to enhance the toxicity in zebrafish embryo.
AID296229Cytotoxicity against human BE2-C cells2007Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12
Heterocyclic substituted cantharidin and norcantharidin analogues--synthesis, protein phosphatase (1 and 2A) inhibition, and anti-cancer activity.
AID296224Cytotoxicity against human MCF7 cells2007Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12
Heterocyclic substituted cantharidin and norcantharidin analogues--synthesis, protein phosphatase (1 and 2A) inhibition, and anti-cancer activity.
AID300554Cytotoxicity against human BE2C cells after 72 hrs by MTT assay2007Bioorganic & medicinal chemistry, Sep-15, Volume: 15, Issue:18
Norcantharimides, synthesis and anticancer activity: Synthesis of new norcantharidin analogues and their anticancer evaluation.
AID526424Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum D6 assessed as inhibition of parasite LDH activity after 72 hrs by malstat reagent method2010Bioorganic & medicinal chemistry letters, Nov-15, Volume: 20, Issue:22
The antiplasmodial activity of norcantharidin analogs.
AID478767Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
Synthesis and biological activity of Delta-5,6-norcantharimides: importance of the 5,6-bridge.
AID1175301Cytotoxicity against human HepG2 cells after 48 hrs by MTT assay2015Bioorganic & medicinal chemistry letters, Jan-15, Volume: 25, Issue:2
Synthesis and biological evaluation of norcantharidin derivatives as protein phosphatase-1 inhibitors.
AID617843Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
Norcantharimide analogues possessing terminal phosphate esters and their anti-cancer activity.
AID1175306Inhibition of protein phosphatase-1 (unknown origin) using phosphopeptide (Lys-Arg-pThr-Ile-Arg) substrate incubated for 60 mins by colorimetric analysis based serine/threonine assay2015Bioorganic & medicinal chemistry letters, Jan-15, Volume: 25, Issue:2
Synthesis and biological evaluation of norcantharidin derivatives as protein phosphatase-1 inhibitors.
AID124930In vivo antitumor activity in SK-Hep-1 sc-Inoculated Xenograft in male nude mice dosed at 4 mg/kg (ip)on days 1,5 and 9; Not active2001Journal of medicinal chemistry, Jun-21, Volume: 44, Issue:13
Potential new antitumor agents from an innovative combination of demethylcantharidin, a modified traditional Chinese medicine, with a platinum moiety.
AID1306338Induction of apoptosis in human MCF7 cells assessed as necrotic cells at 4 uM after 24 hrs by Annexin V-FITC/propidium iodide staining-based flow cytometry (Rvb = 0.021 to 3.8%)2016Bioorganic & medicinal chemistry letters, 07-15, Volume: 26, Issue:14
Design, synthesis and anti-cancer activity evaluation of podophyllotoxin-norcantharidin hybrid drugs.
AID301932Inhibition of bovine brain PP2B2007Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23
Synthesis and biological evaluation of norcantharidin analogues: towards PP1 selectivity.
AID301930Inhibition of PP1 in rabbit skeletal muscle2007Bioorganic & medicinal chemistry, Dec-01, Volume: 15, Issue:23
Synthesis and biological evaluation of norcantharidin analogues: towards PP1 selectivity.
AID478770Cytotoxicity against human A431 cells after 72 hrs by MTT assay2010European journal of medicinal chemistry, May, Volume: 45, Issue:5
Synthesis and biological activity of Delta-5,6-norcantharimides: importance of the 5,6-bridge.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (34)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's17 (50.00)29.6817
2010's16 (47.06)24.3611
2020's1 (2.94)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.34

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.34 (24.57)
Research Supply Index3.56 (2.92)
Research Growth Index5.89 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.34)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other34 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]